A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782 is a phase 2 interventional trial sponsored by Verastem, Inc.. As of 21 Nov 2026, it is recruiting participants. It studies VS-7375 in Non-Small Cell Lung Cancer. The registry lists an enrollment of 105 participants at 26 sites in 4 countries. The registry lists a start date of 22 Jul 2026 and a primary completion date of 30 Jun 2027. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT07659782 |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Verastem, Inc. |
| Enrollment | 105 |
| Registered sites | 26 |
| Countries | 4 |
| Conditions | Non-Small Cell Lung Cancer |
| Drugs | VS-7375 |
| Start | 22 Jul 2026 |
| Primary completion | 30 Jun 2027 |
| Study completion | 31 Dec 2028 |
| Last update posted | 17 Nov 2026 |
| Other registry IDs | EU-CTR / CTIS (EudraCT) 2026-526472-23-00 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Honorhealth Research Institute
Scottsdale
Frank Tsai, MDRecruiting
- Cedars-Sinai Medical Center
Los Angeles
Karen Reckamp, MDRecruiting - Start la
Los Angeles
Navid Hafez, MDRecruiting - Valkyrie Clinical Trials
Los Angeles
David Berz, MDRecruiting
- University of Colorado Cancer Center
Aurora
Tejas Patil, MDRecruiting
- Brcr Global - Coral Springs
Coral Springs
Sumit Sawhney, MDRecruiting - Brcr Global- Tamarac
Tamarac
Andrew Schneider, MDRecruiting - Moffit Cancer Centre
Tampa
Andreas Saltos, MDRecruiting
- Emory Winship Cancer Institute
Atlanta
Jennifer Carlisle, MDRecruiting
- University of Chicago
Chicago
Marina Garassino, MDRecruiting
- Start New Jersey
East Brunswick
Bruno Fang, MDRecruiting
- Memorial Sloan Kettering Cancer Center
New York
Kathryn Arbour, MDRecruiting - Nyu
New York
Rajwanth Veluswamy, MDRecruiting
- University of North Carolina at Chapel Hill
Chapel Hill
Shetal Patel, MD, PhDRecruiting
- Start Fort Worth
Fort Worth
Salwan Almutar, MDRecruiting - Md Anderson Cancer Center
Houston
Marcelo Negrao, MDRecruiting
- University of Utah
Salt Lake City
Matthew Gumbleton, MDRecruiting
- University of Virginia
Charlottesville
Richard Hall, MDRecruiting - Virginia Cancer Specialists
Fairfax
Alexander Spira, MDRecruiting
- Chris O'Brien Lifehouse
Camperdown, New South Wales
Malinda Itchins, BMedSci, MBBS, FRACP, PhDRecruiting - Macquarie University Hospital
Sydney, New South Wales
John Park, BSc MBBS MPH FRACP PhDRecruiting - Icon Cancer Centre South Brisbane
Brisbane, Queensland
Jermaine Coward, BSc, MBBS, MRCP, FRACP, PhDRecruiting - Monash Health
Clayton, Victoria
Surein Arulananda, MBBS BMedSci PhD FRACPRecruiting
- Brcr Global- San Juan
San Juan
Alexandra Deya, MDRecruiting - Brcr Global- Yauco
Yauco
Maryknoll De La Paz, MdRecruiting
- Chu Ucl Namur - Sainte-Elisabeth
Namur
Jean-Charles Goeminne, MDRecruiting
United States, by state
Outside the United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT07659782
Each answer restates registry values shown on this page.
What is NCT07659782?
NCT07659782 is a phase 2 interventional trial sponsored by Verastem, Inc.. It studies VS-7375 in Non-Small Cell Lung Cancer.
Is NCT07659782 recruiting?
As of 21 Nov 2026, it is recruiting participants. 26 of its 26 sites list their own status as recruiting.
Where does NCT07659782 run?
The registry lists 26 sites in 4 countries. Most sites are in these countries: United States (19), Australia (4) and Puerto Rico (2).
Which drugs does NCT07659782 study?
The registered drug and biological interventions are VS-7375.
When is NCT07659782 expected to complete?
The registry lists a primary completion date of 30 Jun 2027 and a study completion date of 31 Dec 2028. The sponsor last updated the record on 17 Nov 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.